Brokerages Anticipate Kura Oncology, Inc. (NASDAQ:KURA) to Post -$0.30 Earnings Per Share

Equities research analysts predict that Kura Oncology, Inc. (NASDAQ:KURAGet Rating) will report earnings per share (EPS) of ($0.30) for the current fiscal quarter, according to Zacks Investment Research. Zero analysts have provided estimates for Kura Oncology’s earnings, with the lowest EPS estimate coming in at ($0.53) and the highest estimate coming in at $0.53. Kura Oncology posted earnings per share of ($0.46) during the same quarter last year, which suggests a positive year-over-year growth rate of 34.8%. The business is scheduled to announce its next earnings report on Monday, January 1st.

According to Zacks, analysts expect that Kura Oncology will report full year earnings of ($2.25) per share for the current fiscal year, with EPS estimates ranging from ($2.41) to ($2.04). For the next year, analysts expect that the business will report earnings of ($2.31) per share, with EPS estimates ranging from ($2.62) to ($2.01). Zacks Investment Research’s earnings per share calculations are an average based on a survey of analysts that cover Kura Oncology.

Kura Oncology (NASDAQ:KURAGet Rating) last posted its quarterly earnings data on Thursday, February 24th. The company reported ($0.49) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.54) by $0.05. During the same period in the previous year, the business posted ($0.45) EPS.

A number of brokerages have issued reports on KURA. SVB Leerink dropped their target price on shares of Kura Oncology from $41.00 to $28.00 and set an “outperform” rating for the company in a report on Friday, February 25th. StockNews.com began coverage on shares of Kura Oncology in a report on Thursday, March 31st. They set a “sell” rating on the stock. Credit Suisse Group lifted their price target on shares of Kura Oncology from $25.00 to $27.00 and gave the stock an “outperform” rating in a research note on Friday, February 25th. BMO Capital Markets boosted their target price on shares of Kura Oncology from $70.00 to $80.00 in a research report on Friday, January 7th. Finally, Zacks Investment Research raised shares of Kura Oncology from a “sell” rating to a “hold” rating in a research report on Wednesday, February 16th. One investment analyst has rated the stock with a sell rating, one has given a hold rating and six have assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Buy” and an average price target of $38.00.

Shares of KURA opened at $15.45 on Friday. Kura Oncology has a fifty-two week low of $11.49 and a fifty-two week high of $30.37. The firm has a 50-day simple moving average of $15.26 and a 200-day simple moving average of $15.49.

A number of institutional investors have recently added to or reduced their stakes in KURA. Deep Track Capital LP acquired a new stake in Kura Oncology during the 4th quarter worth approximately $35,700,000. Invesco Ltd. boosted its position in Kura Oncology by 96.8% during the third quarter. Invesco Ltd. now owns 3,000,140 shares of the company’s stock worth $56,194,000 after purchasing an additional 1,475,350 shares during the period. Deerfield Management Company L.P. Series C boosted its position in shares of Kura Oncology by 51.8% in the fourth quarter. Deerfield Management Company L.P. Series C now owns 3,513,756 shares of the company’s stock valued at $49,193,000 after acquiring an additional 1,198,339 shares during the period. Suvretta Capital Management LLC boosted its position in shares of Kura Oncology by 45.2% in the fourth quarter. Suvretta Capital Management LLC now owns 3,572,419 shares of the company’s stock valued at $50,014,000 after acquiring an additional 1,112,217 shares during the period. Finally, Artal Group S.A. lifted its position in Kura Oncology by 75.0% during the third quarter. Artal Group S.A. now owns 1,050,000 shares of the company’s stock worth $19,667,000 after purchasing an additional 450,000 shares during the period.

Kura Oncology Company Profile (Get Rating)

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer in the United States. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, a small molecule inhibitor of the menin-Lysine K-specific Methyltransferase 2A protein-protein interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; and tipifarnib, an orally bioavailable inhibitor of farnesyl transferase that is in Phase II clinical trials for the treatment of solid tumors and hematologic indications.

Featured Stories

Get a free copy of the Zacks research report on Kura Oncology (KURA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Kura Oncology (NASDAQ:KURA)

Receive News & Ratings for Kura Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kura Oncology and related companies with MarketBeat.com's FREE daily email newsletter.